Squarepoint
GALT icon

Squarepoint’s Galectin Therapeutics GALT Stock Holding History

Squarepoint’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,462
Closed -$68.5K – 4503
2025
Q4 		$68.5K Buy
+16,462
New +$86.7K ﹤0.01% 4100
2024
Q4 		– Sell
-27,435
Closed -$75.4K – 5177
2024
Q3 		$75.4K Sell
27,435
-56,639
-67% -$139K ﹤0.01% 3930
2024
Q2 		$190K Buy
84,074
+36,139
+75% +$110K ﹤0.01% 3674
2024
Q1 		$115K Buy
+47,935
New +$90.7K ﹤0.01% 3772
2022
Q1 		– Sell
-13,182
Closed -$27K – 3088
2021
Q4 		$27K Sell
13,182
-26,009
-66% -$74.3K ﹤0.01% 3076
2021
Q3 		$152K Sell
39,191
-16,937
-30% -$57.4K ﹤0.01% 2586
2021
Q2 		$180K Buy
+56,128
New +$200K ﹤0.01% 2872
2020
Q1 		– Sell
-14,537
Closed -$42K – 2094
2019
Q4 		$42K Buy
14,537
+636
+5% +$2.21K ﹤0.01% 2402
2019
Q3 		$51K Buy
13,901
+3,788
+37% +$13.7K ﹤0.01% 2239
2019
Q2 		$42K Buy
+10,113
New +$43.8K ﹤0.01% 2290
2018
Q4 		– Sell
-29,525
Closed -$177K – 2042
2018
Q3 		$177K Buy
29,525
+12,947
+78% +$71.2K ﹤0.01% 1800
2018
Q2 		$105K Buy
+16,578
New +$80.7K ﹤0.01% 1638

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Squarepoint's GALT Position: Q1 2026 in Review

Squarepoint sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 16,462 shares — an estimated $68.5K sold.

Squarepoint first reported a position in GALT in Q2 2018 and held it in 12 quarters. The position peaked at $190K in Q2 2024. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Squarepoint reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 16,462 Galectin Therapeutics shares in Q1 2026, an estimated $68.5K.
  • Squarepoint first reported a position in Galectin Therapeutics in Q2 2018 and held it in 12 quarters.
  • Squarepoint's Galectin Therapeutics position peaked at $190K in Q2 2024.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.